Evidence map›Paper›PMID 40752013›Full record

ArticleFuture science OA2025

Assessment of the relationship between hematologic parameters, (CPD), in screening for COVID-19 severity in women.

Simone Cristina de Carvalho, Sonia Mara Raboni, Lucas Bochnia Bueno, Bruna Amaral Lapinscki, Sonia Maria Lissa, Ludmilla Louise Moreira Amadeu, Ricardo Rasmussen Petterle, Samuel Ricardo Comar, Meri Bordignon Nogueira

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Simone Cristina de CarvalhoPostgraduate Program in Tocogynecology and Women's Health, Universidade Federal do Paraná, Curitiba, Brazil.
Sonia Mara RaboniPostgraduate Program in Internal Medicine and Health Science, Universidade Federal do Paraná, Curitiba, Brazil.
Lucas Bochnia BuenoPostgraduate Program in Microbiology, Parasitology and Pathology, Universidade Federal do Paraná, Curitiba, Brazil.
Bruna Amaral LapinsckiPostgraduate Program in Internal Medicine and Health Science, Universidade Federal do Paraná, Curitiba, Brazil.
Sonia Maria LissaPostgraduate Program in Tocogynecology and Women's Health, Universidade Federal do Paraná, Curitiba, Brazil.
Ludmilla Louise Moreira AmadeuHematology Laboratory Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, Brazil.
Ricardo Rasmussen PetterleUndergraduate Course in Medicine, Universidade Federal do Paraná, Curitiba, Brazil.
Samuel Ricardo ComarHematology Laboratory Hospital de Clínicas, Universidade Federal do Paraná, Curitiba, Brazil.
Meri Bordignon NogueiraPostgraduate Program in Tocogynecology and Women's Health, Universidade Federal do Paraná, Curitiba, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis study evaluated hematological parameters and cell population data (CPDs) to assess their ability to discriminate between moderate and severe COVID-19 in hospitalized female patients, and to identify potential markers associated with worse outcomes. PATIENTS &

methodsA retrospective study was conducted on 84 adult female COVID-19 patients hospitalized at CHC-UFPR (Brazil) between March 2020 and July 2021. Patients were stratified into moderate (

resultsSignificant differences (

conclusionsHematological parameters, particularly CPDs and NLR, are valuable for early stratification of COVID-19 severity. These automated, rapid, and cost-effective measures can support clinical decision-making. However, CPD usage depends on analyzer availability and lacks standardization across platforms.

Indexed as

COVID-19CPD (cell population data)D-dimermoderate diseaseSARS-CoV-2severe diseasesysmex XN-3100women

Identifiers

PMID40752013
PMCPMC12320868

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.